Scarica l'app Stockscreener
2.07
1.89%
-0.05
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AYTU Giù?
Forum
Previsione
Frazionamento azionario
Aytu Biopharma Inc Borsa (AYTU) Ultime notizie
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Decline in Short Interest - Defense World
Insider Spends US$100k Buying More Shares In Aytu BioPharma - simplywall.st
CEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More Shares - Yahoo Finance
Transcript : Aytu BioPharma, Inc.Special Call - MarketScreener
Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharm - GuruFocus
Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharma Inc (AYTU) - GuruFocus
Aytu Biopharma chief business officer buys $24,999 in stock By Investing.com - Investing.com South Africa
Aytu Biopharma chief business officer buys $24,999 in stock - Investing.com Australia
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock By Investing.com - Investing.com Canada
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock - Investing.com Australia
AYTU BIOPHARMA Executives Increase Stake in Company - TradingView
Aytu BioPharma Announces Closing of Upsized At the Market Public - GuruFocus
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan - ACCESS Newswire
Breakthrough: First Depression Drug Without Sexual Side Effects Gets $16.6M Backing for Q4 Launch - Stock Titan
Aytu BioPharma to commercialise Exxua for MDD in the US - Yahoo Finance
Aytu BioPharma (AYTU) Announces Upsized Public Offering to Fund - GuruFocus
Aytu BioPharma secures exclusive rights to new MDD drug By Investing.com - Investing.com South Africa
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer P - GuruFocus
AYTU Increases Common Stock Offering to 9.6 Million Shares | AYT - GuruFocus
AYTU Increases Common Stock Offering to 9.6 Million Shares | AYTU Stock News - GuruFocus
Aytu BioPharma (AYTU) Secures Exclusive Deal for U.S. Launch of - GuruFocus
Aytu BioPharma secures exclusive rights to new MDD drug - Investing.com
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock | AYTU Stock News - GuruFocus
Aytu BioPharma (AYTU) Secures Exclusive Deal for U.S. Launch of Exxua Tablets | AYTU Stock News - GuruFocus
AytuBioPharma (AYTU) Secures Exclusive Rights to Commercialize EXXUA in the U.S. | AYTU Stock News - GuruFocus
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States | AYTU - GuruFocus
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock - ACCESS Newswire
Aytu BioPharma Secures $14.4M Financing: Major Funds Back EXXUA Depression Drug Commercialization - Stock Titan
New Antidepressant EXXUA Enters $22B Market Without Sexual Side Effects | AYTU Stock News - Stock Titan
AYTU: Lake Street Takes Role as Sole Book-Running Manager | AYTU Stock News - GuruFocus
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Growth in Short Interest - Defense World
Aytu signals ongoing portfolio expansion opportunities as Q3 2025 revenue surges 32% - MSN
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500(TM) - ACCESS Newswire
Aytu BioPharma (AYTU) Reports Significant Revenue Growth in Q3 2 - GuruFocus
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts - MSN
Aytu BioPharma Third Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results | AYTU Stock News - GuruFocus
Aytu BioPharma Inc (AYTU) Q3 2025 Earnings: EPS of $0.21 Beats E - GuruFocus
Why Boot Barn Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Aytu BioPharma Inc (AYTU) Q3 2025 Earnings Call Highlights: Stro - GuruFocus
Aytu BioPharma Reports Strong Q3 2025 Earnings - TipRanks
Aytu Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aytu BioPharma (AYTU) Reports Strong Q3 Earnings Beat - GuruFocus
Earnings call transcript: Aytu BioPharma sees Q3 revenue surge, stock jumps - Investing.com India
Aytu BioPharma Reports Fiscal 2025 Third Quarter Results - TradingView
Transcript : Aytu BioPharma, Inc., Q3 2025 Earnings Call, May 14, 2025 - marketscreener.com
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results - ACCESS Newswire
We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation - simplywall.st
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational a - GuruFocus
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference - ACCESS Newswire
0.28%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):